Fulgent is moving past its pandemic-era business, and that's a good thing.
Neither has a traditional business model, but that could be an asset for both.
Both are experiencing a bit of a hangover from declining COVID-19-related sales.
Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 51.11% and 6.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today...
Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....
Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.